Dr Gordon is a PhD molecular cytogeneticist with over 20 years’ experience in molecular diagnostics.
After working at the Institute of Cancer Research in the 1990s, he moved to a number of companies in the diagnostics field. Firstly, MWG Biotech, then Tecan before joining BlueGnome in 2006.
In 2008, Dr Gordon started the 24sure product line within BlueGnome, aiming to bring BlueGnome’s copy number microarray expertise to pre-implantation genetic screening (PGS).
The vast majority of global PGS is performed using 24sure/VeriSeq PGS, and in 2012 BlueGnome was sold to Illumina.
After briefly working for Illumina, in 2013, Dr Gordon joined Genesis Genetics, a leading global company for PGD and PGS. He was Managing Director for their five USA laboratories and Laboratory Director for two labs in the UK. In 2015, Dr Gordon started the Genesis Serenity NIPT program. In April 2016, Genesis Genetics laboratories were sold to the Cooper Surgical Companies (USA).
Dr Gordon is currently the Direct of Clinical Operations for CooperGenomics UK labs, and is leading the CooperGenomics global business development – outside the US. Dr Gordon is also a UK State Registered Clinical Scientist and is a Fellow of the Royal Society of Biology.